# Lineage Cell Therapeutics (LCTX) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/LCTX
## Company Profile
- Ticker: LCTX
- Exchange: AMEX
- Sector: Biotechnology
- Location: United States
- Tags: Biologics, Biopharma, Diagnostics, Novel Therapies, Immunotherapy, CAR-T Therapy, Stem Cells, Large Molecule Drugs, Oncology
## Stock Data
- Close: 1.16 USD
- Market cap: 319101817.6 USD
- Last updated: 2026-07-17
## Business Overview
Lineage Cell Therapeutics is a cell therapy company focused on translating complex living-cell science into clinically meaningful treatments for hard-to-treat diseases. Investors usually watch how the platform converts data, manufacturing readiness, and launch execution into a durable oncology or specialty franchise.
## Why The Stock Is Moving

LCTX is trading with a steady catalyst profile while investors wait for the next headline that changes the story.

## Geographic Base

Headquartered in the United States and listed on 美国证券交易所, Lineage Cell Therapeutics sits inside the cell therapy universe where trial execution and regulatory timing can change the investment case quickly.

## Business Model

Lineage Cell Therapeutics follows a platform-led model where readouts, manufacturing progress, and commercialization milestones matter as much as the initial science. The market tends to reprice the stock quickly whenever adoption, safety, or label-expansion signals improve.

## Landscape Position

Compared with larger diversified biotech peers, Lineage Cell Therapeutics sits at the high-catalyst end of the landscape, where cell therapy names can move sharply on data, approvals, and launch milestones.

## Recent News
- 2026-07-20 10:59 EST — [Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA](https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-build-the-most-powerful-ai-factory-in-life-sciences-with-eb3e7bda) — Source: BMYBristol-Myers Squibb Company
- 2026-07-20 07:00 EST — [European Medicines Agency accepts submission to update Bexsero label for 1-dose Meningitis B booster in 10+ year olds](https://biopharmsignal.com/news/GSK/european-medicines-agency-accepts-submission-to-update-bexsero-label-for-1-dose--8906d096) — Source: GSK plc
- 2026-07-17 09:00 EST — [GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)](https://biopharmsignal.com/news/GSK/gsk-provides-an-update-on-calm-1-and-calm-2-phase-iii-trials-for-camlipixant-in--0e112206) — Source: GSK plc
- 2026-07-16 12:31 EST — [Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia](https://biopharmsignal.com/news/MRK/merck-s-lipfendra-enlicitide-is-the-first-and-only-once-daily-oral-pcsk9-inhibit-1b899588) — Source: Merck
- 2026-07-16 12:00 EST — [Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/ALNY/alnylam-to-webcast-conference-call-discussing-second-quarter-2026-financial-resu-458d7635) — Source: Alnylam Pharmaceuticals, Inc.